Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Zhaoke Ophthalmology Ltd. ( (HK:6622) ) is now available.
Zhaoke Ophthalmology announced that its partner Tenpoint Therapeutics has received U.S. FDA approval for YUVEZZI (formerly BRIMOCHOL PF), a preservative-free, once-daily dual-agent eye drop for the treatment of presbyopia, following successful Phase 3 trials that showed statistically significant near-vision improvement with a favorable safety profile and low rates of eye redness. The U.S. approval is expected to significantly accelerate Zhaoke’s commercialization plans for the product across its extensive Asia-Pacific and Middle East partner network, potentially strengthening its position in the rapidly growing presbyopia-treatment segment in regions where there are currently no approved pharmaceutical options for correcting near vision.
The most recent analyst rating on (HK:6622) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Zhaoke Ophthalmology Ltd. stock, see the HK:6622 Stock Forecast page.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is an ophthalmic-focused pharmaceutical company that partners with global biotech firms to commercialize innovative eye-care therapies across the Asia-Pacific region and the Middle East. The company has built a regional commercialization network covering markets including South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan/Hong Kong/Macau, Singapore, Vietnam, and parts of the Middle East, with a focus on addressing large unmet needs such as presbyopia, the age-related loss of near vision affecting hundreds of millions of people in its core geographies.
Average Trading Volume: 920,885
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.88B
Learn more about 6622 stock on TipRanks’ Stock Analysis page.